Leerink downgraded Metsera (MTSR) to Market Perform from Outperform with a price target of $57, down from$77, after Pfizer (PFE) announced an agreement to acquire Metsera for $4.9B upfront and total potential deal value of about$7.3B contingent on hitting various pipeline-related targets. Metsera’s novel obesity pipeline should help drive Pfizer revenue growth beyond 2028, says the analyst, who believes Metsera’s assets could collectively generate greater than $5B in peak sales. Elevate Your Investing S ...